NeuroSense Therapeutics Ltd. (NRSN)

NeuroSense Issues CEO Letter to Shareholders

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition